Semaday vs Wegovy: Comparison Guide

Semaday vs Wegovy: Comparison Guide

The conversation around weight management has evolved significantly in recent years, with new medications offering promising options for many. Two names you might hear are Wegovy and Semaday. Both are semaglutide brand names, but understanding their differences is crucial for making informed and safe decisions about your health.

This guide provides a clear, evidence-aware comparison to help you understand the landscape of these treatments. It's designed to give you foundational knowledge so you can have a more productive conversation with a medical professional. Consult your healthcare provider before starting any medication.

What is Semaglutide? The Active Ingredient

To understand Wegovy and "Semaday," we first need to talk about semaglutide. Semaglutide is the active pharmaceutical ingredient at the heart of this discussion. It's a glucagon-like peptide-1 (GLP-1) receptor agonist.

In simple terms, semaglutide works by mimicking a natural hormone in your body that targets areas of the brain involved in appetite regulation. It helps reduce hunger, increase feelings of fullness, and slow down how quickly your stomach empties. This combination can lead to a lower calorie intake and, consequently, weight loss.

What is Wegovy?

Wegovy is the brand name for a specific formulation of semaglutide developed and manufactured by Novo Nordisk. It is a prescription medication administered as a once-weekly injection.

Crucially, Wegovy has undergone extensive clinical trials to establish its safety and effectiveness specifically for chronic weight management in adults with obesity or who are overweight with at least one weight-related condition. As a result, it has received approval from major regulatory bodies like the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA) and, in India, the CDSCO (launched in India in June 2025). This approval means its manufacturing process, dosing, and quality are held to strict, consistent standards.

Understanding "Semaday"

This is where clarity is most important. Semaday is a brand name for semaglutide. Medical Dialogues (March 2026) listed it among the generic semaglutide brands lined up for launch in India by Macleods Pharmaceuticals, after Novo Nordisk's core Indian patent on semaglutide expired in March 2026. As of October 2026 we could not confirm Semaday's launch, strengths, device or approved uses from the company or the regulator, so check the pack and leaflet, and ask your doctor or pharmacist, before relying on any detail. Generic semaglutide brands in India differ in approved use (some are approved for type 2 diabetes only, others also for weight management) and in format (disposable pens, reusable cartridge pens or multi-dose vials). It is not approved by the FDA or EMA, so it is not a US, UK or EU product.

A generic brand approved by India's regulator is different from compounded or unregulated semaglutide, which you may also see sold online. The rest of this guide explains why that distinction matters.

What is Compounding? (Not the Same as Semaday)

Compounding is the practice where a pharmacist combines or alters ingredients to create a medication tailored to the needs of an individual patient. It can be essential for patients who have allergies to certain inactive ingredients in a commercially available drug or who need a different dosage form.

However, when a drug is in shortage, compounding pharmacies are sometimes permitted to prepare a compounded version. The challenge is that compounded drugs are not FDA-approved. This means they do not undergo the same rigorous pre-market review for safety, efficacy, and manufacturing quality that brand-name drugs like Wegovy do.

Regulatory bodies have issued warnings about the risks associated with some compounded semaglutide products. These risks can include using different salt forms of semaglutide (like semaglutide sodium) whose safety and effectiveness have not been evaluated, as well as concerns about sterility and the accuracy of the dosage.

Key Differences: A Head-to-Head Comparison

Let's break down the primary distinctions between Wegovy, a regulator-approved generic semaglutide brand (Semaday is one listed generic name, though its approval and launch were not confirmed as of October 2026), and compounded or unregulated semaglutide.

Active Ingredient

Wegovy, approved generic brands and compounded semaglutide products are all intended to contain semaglutide. With Wegovy and regulator-approved generics, the source, purity, and form of the active ingredient are controlled by the manufacturer and checked by the regulator. With compounded versions, the source and form can vary, and some may use semaglutide salts that are not the same as the active ingredient in the approved drug.

Regulatory Approval and Oversight

This is the most significant difference. Wegovy is approved by the FDA, EMA and CDSCO after large-scale human trials, and is manufactured in a highly controlled and inspected environment. Generic semaglutide brands in India, such as those launched from March 2026, are approved by the CDSCO, typically on the basis of comparison studies with the original product.

Compounded drugs, by their nature, are not FDA-approved. They lack the large-scale clinical data to support their safety and efficacy. While licensed pharmacies operate under state board regulations, the final compounded product itself does not carry the same level of federal regulatory vetting.

Dosing and Delivery Device

Wegovy comes in a proprietary, single-use injector pen designed for ease of use and dose accuracy. It has a specific, clinically tested titration schedule where the dose is gradually increased over several months to improve tolerability and minimize side effects.

Compounded semaglutide is typically provided in vials, requiring the user to draw the medication into a syringe. The dosing instructions may not be based on the same extensive clinical trial data that established the Wegovy titration schedule.

Proven Efficacy and Safety Profile

The clinical trial data for Wegovy is publicly available and has been peer-reviewed. For example, the landmark STEP 1 clinical trial showed that participants taking Wegovy, in conjunction with lifestyle changes, achieved an average weight loss of nearly 15% of their body weight over 68 weeks. The side effect profile is also well-documented from these trials.

Because compounded versions have not undergone such trials, there is no large-scale, reliable data on their specific efficacy or safety. While the active ingredient is the same, differences in formulation, purity, or dosage could potentially lead to different outcomes or side effects.

The most common side effects of semaglutide are nausea, diarrhoea, vomiting, constipation and abdominal pain, usually when starting or after a dose increase.

When to get urgent help: contact a doctor or emergency services straight away for severe stomach pain that does not go away, with or without vomiting and sometimes spreading to the back (possible pancreatitis); pain in the upper right abdomen, fever or yellowing of the skin or eyes (possible gallbladder problems); vomiting or diarrhoea that stops you keeping fluids down (risk of dehydration and kidney injury); or swelling of the face or throat or trouble breathing (possible severe allergic reaction). Semaglutide should not be used by people with a personal or family history of medullary thyroid carcinoma or MEN 2. Tell your doctor if you are pregnant or planning a pregnancy, if you have diabetic eye disease, or if you have surgery or sedation planned. If you also take insulin or a sulfonylurea, your doctor may need to adjust those medicines to lower the risk of low blood sugar.

Making an Informed Choice

Navigating your health journey requires access to clear, reliable information. At Weight Easy, we believe in empowering you with that knowledge. When considering a semaglutide product, it helps to know whether it is the original brand, a regulator-approved generic, or an unregulated or compounded product.

The brand-name option, Wegovy, offers the assurance of extensive clinical trials, consistent manufacturing standards, and a proven safety and efficacy profile. Regulator-approved generics in India contain the same active ingredient (if you are offered Semaday, check that it is CDSCO-approved); check their approved use and device with your pharmacist. Compounded or unregulated products lack this level of data and regulatory oversight.

Your health is your most valuable asset. The safest path forward is always one taken in partnership with a qualified medical professional who understands your complete health history. They can help you evaluate the benefits and risks of all available options, ensuring you choose a treatment that is both effective and, most importantly, safe for you. Consult your healthcare provider before starting any medication.

Sources

• https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss
• https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
• https://www.ema.europa.eu/en/medicines/human/EPAR/wegovy
• https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
• https://www.wegovy.com/
• Wegovy US prescribing information (revised June 2026): https://www.novo-pi.com/wegovy.pdf
• BioSpectrum India: Novo Nordisk India partners with Emcure Pharma to commercialise Poviztra (notes Wegovy's June 2025 India launch): https://biospectrumindia.com/news/16/26901/novo-nordisk-india-partners-with-emcure-pharma-to-commercialise-poviztra-in-india.html
• Medical Dialogues: India's semaglutide market set for generic boom as patents expire, over 50 brands lined up for launch (March 2026): https://medicaldialogues.in/news/industry/pharma/indias-semaglutide-market-set-for-generic-boom-as-patents-expire-over-50-brands-lined-up-for-launch-see-full-list-165838
• Biopharma APAC: Semaglutide generics, six months in: every launch in India (October 2026): https://biopharmaapac.com/analysis/23/8540/semaglutide-generics-six-months-in-every-launch-in-india-every-price-and-where-china-stands.html
• Pearce IP: Generic semaglutide launches in India (March 2026): https://www.pearceip.law/2026/03/21/generic-semaglutide-launches-in-india-including-by-dr-reddys-zydus-alkem-sun-pharma-glenmark/